Poly(ADP-ribose) polymerases, commonly referred to as PARPs, are a critical family of enzymes involved in various cellular processes, particularly those concerning DNA repair. These enzymes catalyze the addition of ADP-ribose to proteins, which plays a pivotal role in the cellular response to DNA damage, chromatin remodeling, and transcriptional regulation. There are seventeen members of this family in humans, each exhibiting distinct biological functions and therapeutic targeting possibilities.

The Role of PARPs in Cancer Treatment

The inhibition of PARP1 and PARP2 is particularly significant in cancer therapy, especially for tumors displaying defective homologous recombination, such as those with BRCA mutations. Blocking these enzymes hampers the cell’s ability to repair single-strand breaks in DNA, leading to synthetic lethality. This has opened avenues for developing PARP inhibitors that serve as effective treatments for certain cancers. Moreover, some members of the PARP family, such as tankyrases, influence cell growth and Wnt/β-catenin signaling, further enriching the landscape of potential therapeutic targets.

To successfully assess potential drug candidates, it is crucial to evaluate not only the catalytic inhibition of PARPs but also their trapping on DNA within cellular contexts. This comprehensive approach ensures a better prediction of the in vivo activity and safety profiles of the compounds being tested.

Comprehensive In Vitro PARP Screening Services

Creative Bioarray offers advanced in vitro screening services to thoroughly evaluate the inhibitory capacity of various compounds against PARP enzymes, thereby accelerating the drug discovery process. Our offerings include:

• Screening for PARP inhibitors: Assessing compounds for their ability to inhibit PARP activity.
• Single-point concentration and IC50 determination: Establishing the effective concentration of inhibitors required for half-maximal inhibition.

Assay Details

Our screening encompasses two primary assay types:

• Biochemical catalytic inhibition: Utilizing recombinant PARP enzymes, this assay measures the compounds’ ability to block ADP-ribosylation of DNA or protein substrates, indicative of their inhibitory effects.
• PARP–DNA Trapping (Fluorescence Polarization): Designed to monitor the binding interaction between PARP and fluorescently labeled DNA. Some inhibitors encourage PARP “trapping,” observable through increased fluorescence polarization signals.

List of Targets

Our screening services address a variety of PARP family members, including but not limited to:

• PARP1, PARP2, PARP3
• PARP5a, PARP5b, PARP6
• Additional targets can be included based on specific project requirements.

Service Highlights

With our screening services, clients benefit from:

• High-throughput capabilities: We employ automated platforms, allowing efficient processing of numerous compound samples, thus expediting screening timelines.
• Reliable data generation: Adherence to rigorous industry standards ensures reproducibility and trust in the results.
• Customizable protocols: Support for specific project needs, encompassing diverse concentration gradients and targeted PARP subtypes.
• Expert technical assistance: Our team is equipped to provide guidance tailored to your research objectives.

Creative Bioarray’s PARP Screening Services represent an invaluable resource for drug discovery and development, helping researchers identify and optimize promising PARP inhibitors swiftly. For queries and discussions on how we can assist your research endeavors, please reach out to us.